Issued Patents 2025
Showing 1–9 of 9 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12410259 | CD47 targeted therapies for the treatment of infectious disease | Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune | 2025-09-09 |
| 12370243 | Non-genotoxic conditioning regimen for stem cell transplantation | Judith A. Shizuru, Akanksha Chhabra, Benson M. George | 2025-07-29 |
| 12318448 | Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells | Mingye Feng, Jens-Peter Volkmer | 2025-06-03 |
| 12274746 | Dosing parameters for CD47 targeting therapies to hematologic malignancies | Ravindra Majeti, Mark P. Chao, Jie Liu, Jens-Peter Volkmer | 2025-04-15 |
| 12258399 | Methods for achieving therapeutically effective doses of anti-CD47 agents | Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska +2 more | 2025-03-25 |
| 12258403 | Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody | Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska +2 more | 2025-03-25 |
| 12233093 | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling | Judith A. Shizuru, Kipp Andrew Weiskopf, Aaron Michael Ring, Akanksha Chhabra, Peter Schnorr | 2025-02-25 |
| 12195532 | High affinity SIRP-alpha reagents and methods of using | Aaron Michael Ring, Kenan Christopher Garcia, Kipp Andrew Weiskopf, Aron Levin | 2025-01-14 |
| 12194093 | Dosing parameters for CD47 targeting therapies to hematologic malignancies | Ravindra Majeti, Mark P. Chao, Jie Liu, Jens-Peter Volkmer | 2025-01-14 |